Table 2:

Adverse events that were grade 3 or higher and at least possibly related to study drug(s).

	Arm A (cediranib alone), n (%)	Arm B (cediranib with lenalidomide) (%)
Fatigue	10 (26)	18 (26)
Hypertension	10 (26)	19 (28)
Diarrhea	6 (15)	8 (12)
Hand foot syndrome	6 (15)	5(7.2)
Oral mucositis	3 (7.7)	3 (4.3)
Proteinuria	2 (5.1)	6 (8.7)
Generalized muscle weakness	0 (0)	4 (5.8)
Anorexia	3 (7.7)	2 (2.9)
Syncope	2 (5.1)	1 (1.4)
Vomiting	0 0)	1 (1.4)
Hypophosphatemia	1 (2.6)	4 (5.8)
Hypokalemia	1 (2.6)	3 (4.3)
Thromboembolic event	1 (2.6)	2 (2.9)
Neutropenia	1 (2.6)	11 (16)
Thrombocytopenia	0 (0)	3 (4.3)
White blood cell count decreased	0 (0)	3 (4.3)
Stroke	0 (0)	1 (1.4)
Sinus bradycardia	0 (0)	1 (1.4)
Rash maculo-papular	0 (0)	2 (2.9)
Pneumothorax	0 (0)	1 (1.4)
Pharyngolaryngeal pain	0 (0)	1 (1.4)
Pancreatitis	0 (0)	1 (1.4)
Oral dysesthesia	0 (0)	1 (1.4)
Nausea	0 (0)	1 (1.4)
Muscle weakness upper limb	0 (0)	1 (1.4)
Lung infection	0 (0)	1 (1.4)
Leukocytosis	0 (0)	1 (1.4)
Hypophosphatemia	0 (0)	4 (5.8)
Hypokalemia	0 (0)	3 (4.3)
Hypocalcemia	0 (0)	3 (4.3)
Hypercalcemia	0 (0)	1 (1.4)
Hepatobiliary disorder-other	0 (0)	1 (1.4)
Fall	0 (0)	1 (1.4)
Ejection fraction increased	0 (0)	1 (1.4)
Ear pain	0 (0)	1 (1.4)
Dyspnea	0 (0)	2 (2.9)
Dizziness	0 (0)	1 (1.4)
Delirium	0 (0)	1 (1.4)
Dehydration	0 (0)	2 (2.9)
Creatinine increased	0 (0)	1 (1.4)
Colitis	0 (0)	1 (1.4)
Blood bilirubin increased	0 (0)	2 (2.9)
Aspartate aminotransferase increased	0 (0)	1 (1.4)
Anemia	0 (0)	1 (1.4)
Weight loss	1 (2.6)	3 (4.3)
Lymphocyte count decreased	2 (5.1)	3 (4.3)
Hyponatremia	1 (2.6)	1 (1.4)
Lymphopenia	0 (0)	3 (4.3)
Alanine aminotransferase increased	0	3 (4.3)
Peripheral ischemia	1 (2.6)	0 (0)
Abdominal pain	1 (2.6)	1 (1.4)